Clinical Experience With the Use of a 675 nm Laser System With a Faster Treatment Strategy for Melasma in Indian Patients
Abstract
Background: Melasma is a commonly acquired hyperpigmentation disorder.
Objectives: This is a retrospective, clinical study conducted to evaluate the use of 675 nm wavelength laser treatment in Indian patients affected by facial melasma.
Methods: A total of 52 patients with clinically diagnosed melasma were treated with a 675 nm laser system. All participants underwent 4 treatment sessions, each performed at 27 ± 7 day intervals. Patient's pigment reduction and skin homogeneity were assessed with photographic documentation and with the use of the modified Melasma Area and Severity Index at baseline, and 3-month follow-up after the last laser treatment. In addition, patients’ satisfaction scores were evaluated.
Results: Modified Melasma Area and Severity Index score significantly decreased from 3.8 ± 2.3 at baseline to 2.8 ± 1.7 after treatment. The photographic assessment was consistent with a reduction in pigmentation following treatment. Concerning patient satisfaction scores, 13% of participants reported not being satisfied, 29% were slightly satisfied, 32% were moderately satisfied, and 26% were very satisfied with the overall treatment outcome. There were no major adverse effects reported during the treatment period.
Conclusions: The application of the 675 nm laser was associated with short-term improvement to reduce pigmentary symptoms associated with facial melasma in both Indian men and women. However, the retrospective design, absence of a control group, and relatively short follow-up period limit the strength of these findings. Further prospective controlled studies with longer follow-up are needed to confirm efficacy and durability of results.
Level of Evidence: 4 (Therapeutic):
Related
- Multimodal lifestyle intervention during neoadjuvant chemotherapy in patients with early breast cancer as a strategy to improve treatment response: Protocol of the DIANA randomized clinical trial
- Clinical and Demographic Characteristics of Patients with Pulmonary Large-Cell Neuroendocrine Carcinoma: A Single-Center Experience
- Clinical manifestations, genetic characteristics and laboratory markers of patients with epidermolysis bullosa: a single tertiary referral center experience
- Neuro-endoscopic assisted small bone window treatment for acute subdural hematoma in young and middle aged patients: preliminary experience and techniques exploration of 6 cases
- Surgical Treatment of Rare Multiple Cardiac Myxomas: A 13-Year Clinical Experience at a Single Institution.
BibTeX
@article{joshi2026clinical,
title = {{Clinical Experience With the Use of a 675 nm Laser System With a Faster Treatment Strategy for Melasma in Indian Patients}},
author = {Ruta Joshi and Ojas Kulkarni and Irene Fusco and Tiziano Zingoni and Dipak Kulkarni and Swapnil Shah},
journal = {Aesthetic Surgery Journal. Open Forum},
year = {2026},
month = oct,
doi = {10.1093/asjof/ojag191},
url = {https://doi.org/10.1093/asjof/ojag191},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Clinical Experience With the Use of a 675 nm Laser System With a Faster Treatment Strategy for Melasma in Indian Patients
AU - Ruta Joshi
AU - Ojas Kulkarni
AU - Irene Fusco
AU - Tiziano Zingoni
AU - Dipak Kulkarni
AU - Swapnil Shah
PY - 2026
DA - 2026/10/01
JO - Aesthetic Surgery Journal. Open Forum
DO - 10.1093/asjof/ojag191
UR - https://doi.org/10.1093/asjof/ojag191
AB - Background: Melasma is a commonly acquired hyperpigmentation disorder. Objectives: This is a retrospective, clinical study conducted to evaluate the use of 675 nm wavelength laser treatment in Indian patients affected by facial melasma. Methods: A total of 52 patients with clinically diagnosed melasma were treated with a 675 nm laser system. All participants underwent 4 treatment sessions, each performed at 27 ± 7 day intervals. Patient's pigment reduction and skin homogeneity were assessed with photographic documentation and with the use of the modified Melasma Area and Severity Index at baseline, and 3-month follow-up after the last laser treatment. In addition, patients’ satisfaction scores were evaluated. Results: Modified Melasma Area and Severity Index score significantly decreased from 3.8 ± 2.3 at baseline to 2.8 ± 1.7 after treatment. The photographic assessment was consistent with a reduction in pigmentation following treatment. Concerning patient satisfaction scores, 13% of participants reported not being satisfied, 29% were slightly satisfied, 32% were moderately satisfied, and 26% were very satisfied with the overall treatment outcome. There were no major adverse effects reported during the treatment period. Conclusions: The application of the 675 nm laser was associated with short-term improvement to reduce pigmentary symptoms associated with facial melasma in both Indian men and women. However, the retrospective design, absence of a control group, and relatively short follow-up period limit the strength of these findings. Further prospective controlled studies with longer follow-up are needed to confirm efficacy and durability of results. Level of Evidence: 4 (Therapeutic):
SN - 2631-4797
ER -